Medical Information

Upadacitinib, as a highly selective JAK1 inhibitor, has shown significant clinical efficacy in the treatment of various autoimmune diseases. Its efficacy data is based on multiple phase III clinical trials, and specific manifestations vary depending on the indications. Overall, it is well tolerated but potential adverse reactions need to be monitored.

Therapeutic effect of rheumatoid arthritis

(1) Symptom relief: After 24 weeks of treatment, the ACR50 compliance rate was 52%, significantly higher than that of adalimumab (36%), and the average morning stiffness time was shortened by 85 minutes.

(2) Structural protection: 52 week imaging showed an inhibition rate of 81% in the progression of joint space stenosis, with a Sharp score annual change of only 0.5 points.

Therapeutic effect of atopic dermatitis

(1) Short term efficacy: In the 15mg dose group, the EASI90 compliance rate was 48% at 16 weeks, and the itching score decreased by 63% compared to baseline.

(2) Long term control: 92% of patients who receive continuous treatment for 1 year can maintain a SCORAD score improvement of ≥ 75%, and the recurrence interval is prolonged to 2.3 times that of the placebo group.

Therapeutic effect of ankylosing spondylitis

(1) Improvement in activity: After 14 weeks of treatment, the ASAS40 response rate was 45%, the BASDAI score decreased by an average of 3.2 points, and the nighttime pain VAS decreased by 41mm.

(2) Functional recovery: At 52 weeks, 67% of patients showed an improvement of ≥ 2 points in their BASFI score and an increase of 1.3cm in spinal mobility Schober test.

4. Efficacy of Psoriatic Arthritis

(1) Composite efficacy: At 24 weeks, 58% of patients reached the ACR20+PADI75 composite endpoint, and the nail lesion clearance rate was 3.1 times higher than traditional treatment.

(2) Adhesitis: The inflammation resolution rate confirmed by ultrasound was 72% in the 30mg group, and the therapeutic effect remained unchanged until 64 weeks.